How HiveProspect decides what deserves another look

Where evidence comes from

ClinicalTrials.gov supplies trial context. SEC filings provide dated company statements. NCBI E-utilities supplies PubMed records. Exact sources, dates and supporting text remain attached.

A source fact describes the record. It does not make every claim in that record true.

Human Signal

Check the asset's treatment relationship, human population, indication, exposure, endpoints and contradictory results. A publication count, completed trial or phase does not prove efficacy or safety.

Relevant attribution is a reviewable assessment, not an automatic clinical conclusion.

Cheap Truth

Define the next decision, the objective endpoint and practical burden: patients, sites, procedures, follow-up, dosing and monitoring. Costs require explicit scoped assumptions. Low historical enrollment is not a study budget.

Rights and Acquirability

Sponsor ≠ owner. Patent assignee ≠ commercial controller. Company acquisition ≠ proven asset title. Check current instruments, territory, indication, options, liens, consents and data/CMC transfer.

Historical recipients and contact routes are diligence leads, not proof of authority or availability.

Rescueability

Distinguish biology and safety from financing, strategy and trial execution. A failed company does not prove a viable drug. A failed endpoint does not by itself prove failed biology. Strong negative evidence must not be averaged away.

Why UNKNOWN exists

Missing support is not a positive or negative finding. Unknowns guide the next document request or experiment. They never become favorable ratings to improve a card.